Liquid Biopsy in Non-Small Cell Lung Cancer

Molina-Vila, Miguel Ángel; Mayo‐de‐las‐Casas, Clara; Giménez‐Capitán, Ana; Jordana‐Ariza, Núria; Garzón, Mónica; Balada, Ariadna; Villatoro, Sergi; Teixidó, Cristina; García‐Peláez, Beatriz; Aguado, Cristina; Catalán, María José; Campos, Raquel Munhoz da Silveira; Pérez-Rosado, Ana; Bertrán-Alamillo, Jordi; Martínez‐Bueno, Alejandro; Gil, M.L. Vilardell; González‐Cao, María; González, Xavier; Morales-Espinosa, Daniela; Viteri, Santiago; Karachaliou, Niki; Rosell, Rafael

doi:10.3389/fmed.2016.00069

Cited by 46 publications

(49 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the standard genotyping approach includes invasive tissue biopsy, its clinical utility is limited by a lack of available tissue, potential complications, and patient discomfort . Liquid biopsies, such as those evaluating circulating tumor DNA or RNA, circulating tumor cells, and exosomes, are potentially useful for the analysis of tumor cell genetics using blood samples in patients with malignancies, and these approaches have been increasingly translated from research to clinical practice . For example, EGFR mutation testing using blood samples in advanced NSCLC patients is feasible and can be utilized in patient selection for targeted therapy in conditions where tissue testing cannot be achieved .…”

Section: Discussionmentioning

confidence: 99%

“…26 Liquid biopsies, such as those evaluating circulating tumor DNA or RNA, circulating tumor cells, and exosomes, are potentially useful for the analysis of tumor cell genetics using blood samples in patients with malignancies, and these approaches have been increasingly translated from research to clinical practice. [27][28][29][30] For example, EGFR mutation testing using blood samples in advanced NSCLC patients is feasible and can be utilized in patient selection for targeted therapy in conditions where tissue testing cannot be achieved. 25,[31][32][33][34] In the current study, approximately half of the patients expected the development of non-invasive approaches, although bloodbased testing is considered to complement tissue biopsy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Background Treatment strategies for patients with non‐small cell lung cancer (NSCLC) depend on various factors including physical condition, complications, tumor histology, and molecular profiling. Even if initial chemotherapy is efficacious, almost all patients develop treatment resistance. Invasive rebiopsy from sites of recurrence might provide insight into resistance mechanisms and aid in the selection of suitable sequential antitumor drugs. However, invasive rebiopsy might be challenging because of limited tissue availability and patient burden. Therefore, this study aimed to assess awareness of invasive rebiopsy among non‐small cell lung cancer patients. Methods This prospective questionnaire survey was performed between June 2015 and March 2016 in patients with advanced non‐small cell lung cancer. The survey was carried out at two time points: before starting first‐line chemotherapy (cohort 1), and at the time of disease progression after initial chemotherapy, but before second‐line chemotherapy (cohort 2). Results In this study, 50 and 30 patients were enrolled in cohorts 1 and 2, respectively. In cohort 1, 37 (74%) patients agreed to rebiopsy, if disease progression occurred, whereas 18 (60%) patients in cohort 2 agreed to invasive rebiopsy at disease progression. The primary reasons for rebiopsy rejection were poor physical condition and patient burden related to the initial biopsy. Seven patients answered the survey questions during the treatment course, and the acceptance rate was lower among patients who agreed to rebiopsy at disease progression than before treatment. Conclusions Invasive rebiopsy can lead to distress in some patients. To improve the consent rate for tissue rebiopsy, treatment strategies including rebiopsy should be discussed with patients during the early treatment phase.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Accordingly, there is a need for a minimally invasive and specific test for disease monitoring, which could be beneficial for patients with cervical cancer. Circulating cfDNA has been widely evaluated using liquid biopsies for detecting cancer, monitoring disease, characterizing drug targets, and uncovering resistance in various tumors [40,[42][43][44].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of circulating tumor DNA as an effective biomarker in cervical cancer: a meta-analysis

C²,

Qiu

et al. 2019

Preprint

View full text Add to dashboard Cite

The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer and contains abundant information regarding tumor characteristics, highlighting its potential diagnostic value in the clinical setting. However, the diagnostic value of cfDNA as a biomarker in cervical cancer remains unclear. Here, we performed a metaanalysis to evaluate the applications of ctDNA as a biomarker in cervical cancer. A systematic literature search was performed using PubMed, Embase, and WANFANG MED ONLINE databases up to March 18, 2019. All literature was analyzed using Meta Disc 1.4 and STATA 14.0 software. Diagnostic measures of accuracy of ctDNA in cervical cancer were pooled and 2investigated. Fifteen studies comprising 1109 patients with cervical cancer met our inclusion criteria and were subjected to analysis. The pooled sensitivity and specificity were 0.52 (95% confidence interval [CI], 0.33-0.71) and 0.97 (95% CI, 0.91-0.99), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 16.0 (95% CI, 5.5-46.4) and 0.50 (95% CI, 0.33-0.75), respectively. The diagnostic odds ratio was 32 (95% CI, 10-108), and the area under the summary receiver operating characteristic curve was 0.92 (95% CI, 0.90-0.94). There was no significant publication bias observed. In the included studies, ctDNA showed clear diagnostic value for diagnosing and monitoring cervical cancer. Our metaanalysis suggested that detection of human papilloma virus ctDNA in patients with cervical cancer could be used as a noninvasive early dynamic biomarker of tumors, with high specificity and moderate sensitivity. Further large-scale prospective studies are required to validate the factors that may influence the accuracy of cervical cancer diagnosis and monitoring.

show abstract

“…In liquid biopsy, bodily fluids (largely blood and urine) are used for diagnosis, instead of collecting tissue samples, which are generally obtained through surgical procedures. Due to its immense potential liquid biopsy-based tests are predicted to become a standard tool for diagnostic, prognostic, and predictive information in nonsmall cell lung cancer (Molina-Vila et al, 2016). Mainly circulating tumor cells (CTCs), circulating-free DNA (cfDNA), and exosomes are analyzed in liquid biopsies.…”

Section: Theranostics Applications Of Exosomes In Lung Cancermentioning

confidence: 99%

Exosomes as Theranostics for Lung Cancer

Srivastava

Amreddy

Razaq

et al. 2018

Advances in Cancer Research

View full text Add to dashboard Cite

Extensive research in genetics and genomics has revealed that lung cancer is a physiologically complex and genetically heterogeneous disease. Although molecular targets that can yield favorable response have been identified, those targets cannot be exploited due to the lack of suitable drug carriers. Furthermore, lung cancer often is diagnosed at an advanced stage when the disease has metastasized. Conventional treatments are not effective for treating metastatic lung cancer. Targeted therapeutics while beneficial has challenges that include poor tumor-targeting, off-target effects, and development of resistance to therapy. Therefore, improved drug delivery systems that can deliver drugs specifically to tumor will produce improved treatment outcomes. Exosomes have a natural ability to carry functional biomolecules, such as small RNAs, DNAs, and proteins, in their lumen. This property makes exosomes attractive for use in drug delivery and molecular diagnosis. Moreover, exosomes can be attached to nanoparticles and used for high precision imaging. Exosomes are now considered an important component in liquid biopsy assessments, which are useful for detecting cancers, including lung cancer. Several studies are currently underway to develop methods of exploiting exosomes for use as efficient drug delivery vehicles and to develop novel diagnostic modalities. This chapter summarizes the current status of exosome studies with regard to their use as theranostics in lung cancer. Examples from other cancers have also been cited to illustrate the extensive applicability of exosomes to therapy and diagnosis.

show abstract

Liquid Biopsy in Non-Small Cell Lung Cancer

Cited by 46 publications

References 99 publications

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer

Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer

Diagnostic value of circulating tumor DNA as an effective biomarker in cervical cancer: a meta-analysis

Exosomes as Theranostics for Lung Cancer

Contact Info

Product

Resources

About